Noncanonical TRAIL Signaling Promotes Myeloid-Derived Suppressor Cell Abundance and Tumor Growth in Cholangiocarcinoma

[1]  G. Gores,et al.  Cholangiocarcinoma — novel biological insights and therapeutic strategies , 2023, Nature Reviews Clinical Oncology.

[2]  S. Barry,et al.  Therapeutic targeting of tumour myeloid cells , 2023, Nature Reviews Cancer.

[3]  X. Wang,et al.  Multiregional single-cell dissection of tumor and immune cells reveals stable lock-and-key features in liver cancer , 2022, Nature Communications.

[4]  R. Bernards,et al.  cFLIP suppression and DR5 activation sensitize senescent cancer cells to senolysis , 2022, Nature Cancer.

[5]  Chun Jimmie Ye,et al.  Circulating monocytes associated with anti-PD-1 resistance in human biliary cancer induce T cell paralysis , 2022, Cell reports.

[6]  Ruibin Xi,et al.  Publisher Correction: Single-cell transcriptomic analysis suggests two molecularly distinct subtypes of intrahepatic cholangiocarcinoma , 2022, Nature Communications.

[7]  M. Rebelatto,et al.  Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study. , 2022, The lancet. Gastroenterology & hepatology.

[8]  Martin S. Taylor,et al.  In Vivo Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma , 2022, Cancer research.

[9]  S. Gottschalk,et al.  Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer , 2021, Journal for ImmunoTherapy of Cancer.

[10]  J. Yeh,et al.  GM-CSF drives myelopoiesis, recruitment and polarisation of tumour-associated macrophages in cholangiocarcinoma and systemic blockade facilitates antitumour immunity , 2021, Gut.

[11]  Shannon K. Boi,et al.  Obesity diminishes response to PD-1-based immunotherapies in renal cancer , 2020, Journal for ImmunoTherapy of Cancer.

[12]  V. Ivanisenko,et al.  Pharmacological targeting of c-FLIPL and Bcl-2 family members promotes apoptosis in CD95L-resistant cells , 2020, Scientific Reports.

[13]  P. Krebs,et al.  The multifaceted role of TRAIL signaling in cancer and immunity , 2020, The FEBS journal.

[14]  Raphael Gottardo,et al.  Integrated analysis of multimodal single-cell data , 2020, Cell.

[15]  Chen Wang,et al.  Targeting tumor-associated macrophages and granulocytic-myeloid-derived suppressor cells augments pd-1 blockade in cholangiocarcinoma. , 2020, The Journal of clinical investigation.

[16]  E. Jaffee,et al.  The tumour microenvironment in pancreatic cancer — clinical challenges and opportunities , 2020, Nature Reviews Clinical Oncology.

[17]  Hong Wang,et al.  Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE‐158 and KEYNOTE‐028 studies , 2020, International journal of cancer.

[18]  D. Calvisi,et al.  Loss of Fbxw7 synergizes with activated AKT signaling to promote c-Myc dependent cholangiocarcinogenesis. , 2019, Journal of hepatology.

[19]  Jonathan M. Hernandez,et al.  Tumor Cell Biodiversity Drives Microenvironmental Reprogramming in Liver Cancer. , 2019, Cancer cell.

[20]  C. Ries,et al.  Therapeutic targeting of macrophages enhances chemotherapy efficacy by unleashing type I interferon response , 2019, Nature Cell Biology.

[21]  S. Bicciato,et al.  Induction of immunosuppressive functions and NF-κB by FLIP in monocytes , 2018, Nature Communications.

[22]  Zev J. Gartner,et al.  DoubletFinder: Doublet detection in single-cell RNA sequencing data using artificial nearest neighbors , 2018, bioRxiv.

[23]  D. Gabrilovich,et al.  Myeloid-derived suppressor cells coming of age , 2018, Nature Immunology.

[24]  G. Gores,et al.  YAP-associated chromosomal instability and cholangiocarcinoma in mice , 2017, Oncotarget.

[25]  Y. Shaked,et al.  CCR5 Directs the Mobilization of CD11b+Gr1+Ly6Clow Polymorphonuclear Myeloid Cells from the Bone Marrow to the Blood to Support Tumor Development. , 2017, Cell reports.

[26]  Bin Tean Teh,et al.  Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma. , 2017, Cancer discovery.

[27]  A. Chakravarthy,et al.  The TRAIL-Induced Cancer Secretome Promotes a Tumor-Supportive Immune Microenvironment via CCR2 , 2017, Molecular cell.

[28]  Philippe Foubert,et al.  PI3Kγ is a molecular switch that controls immune suppression , 2016, Nature.

[29]  R. V. van Ginkel,et al.  Programmed Death Ligand 1 (PD-L1)-targeted TRAIL combines PD-L1-mediated checkpoint inhibition with TRAIL-mediated apoptosis induction , 2016, Oncoimmunology.

[30]  Shannon M. White,et al.  Yes-Associated Protein Mediates Immune Reprogramming in Pancreatic Ductal Adenocarcinoma , 2016, Oncogene.

[31]  G. Gores,et al.  IL‐33 facilitates oncogene‐induced cholangiocarcinoma in mice by an interleukin‐6‐sensitive mechanism , 2015, Hepatology.

[32]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[33]  N. Hockstein,et al.  ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis. , 2014, The Journal of clinical investigation.

[34]  L. Boon,et al.  Effective TRAIL-based immunotherapy requires both plasmacytoid and CD8α dendritic cells , 2014, Cancer Immunology, Immunotherapy.

[35]  C. Meyer,et al.  Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab , 2014, Cancer Immunology, Immunotherapy.

[36]  S. Fulda,et al.  The dark side of TRAIL signaling , 2013, Cell Death and Differentiation.

[37]  S. Markovic,et al.  Endogenous tumor-reactive CD8+ T cells are differentiated effector cells expressing high levels of CD11a and PD-1 but are unable to control tumor growth , 2013, Oncoimmunology.

[38]  G. Peters,et al.  Non-canonical kinase signaling by the death ligand TRAIL in cancer cells: discord in the death receptor family , 2013, Cell Death and Differentiation.

[39]  A. Zhu,et al.  Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma. , 2012, Cancer research.

[40]  L. Norian,et al.  Eradication of Metastatic Renal Cell Carcinoma after Adenovirus-Encoded TNF-Related Apoptosis-Inducing Ligand (TRAIL)/CpG Immunotherapy , 2012, PloS one.

[41]  S. Bicciato,et al.  Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. , 2010, Immunity.

[42]  H. Gollnick,et al.  Suppression of cFLIP is sufficient to sensitize human melanoma cells to TRAIL- and CD95L-mediated apoptosis , 2008, Oncogene.

[43]  L. Mariani,et al.  Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  I. Jeremias,et al.  TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-κB , 2003, Oncogene.

[45]  M. Smyth,et al.  Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (Trail) Contributes to Interferon γ–Dependent Natural Killer Cell Protection from Tumor Metastasis , 2001, The Journal of experimental medicine.

[46]  A. Tannapfel,et al.  Mutations of p53 Tumor Suppressor Gene, Apoptosis, and Proliferation in Intrahepatic Cholangiocellular Carcinoma of the Liver , 2000, Digestive Diseases and Sciences.

[47]  W. Reith,et al.  Conditional gene targeting in macrophages and granulocytes using LysMcre mice , 1999, Transgenic Research.

[48]  E. Alnemri,et al.  Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor. , 1999, Cancer research.

[49]  J. Tschopp,et al.  TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB. , 1997, Immunity.

[50]  Henning Walczak,et al.  TRAIL‐R2: a novel apoptosis‐mediating receptor for TRAIL , 1997, The EMBO journal.

[51]  Arul M. Chinnaiyan,et al.  The Receptor for the Cytotoxic Ligand TRAIL , 1997, Science.

[52]  Acknowledgments , 1993, Experimental Gerontology.

[53]  G. Gores,et al.  Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells. , 2006, American journal of physiology. Gastrointestinal and liver physiology.

[54]  Michael Karin,et al.  IKK/NF-kappaB signaling: balancing life and death--a new approach to cancer therapy. , 2005, The Journal of clinical investigation.